Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Atara Biotherap (ATRA)

Atara Biotherap (ATRA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 40,809
  • Shares Outstanding, K 8,178
  • Annual Sales, $ 120,770 K
  • Annual Income, $ 32,690 K
  • EBIT $ 36 M
  • EBITDA $ 38 M
  • 60-Month Beta -0.34
  • Price/Sales 0.35
  • Price/Cash Flow 1.06
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year $3.50
  • Growth Rate Est. (year over year) +28,442.86%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.30 +16.04%
on 03/30/26
7.30 -31.64%
on 03/09/26
-0.18 (-3.48%)
since 03/06/26
3-Month
3.92 +27.29%
on 02/23/26
17.98 -72.25%
on 01/09/26
-9.58 (-65.75%)
since 01/06/26
52-Week
3.92 +27.29%
on 02/23/26
19.15 -73.94%
on 01/05/26
-0.60 (-10.74%)
since 04/04/25

Most Recent Stories

More News
ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit

NEW YORK , April 4, 2026 /PRNewswire/ -- 

ATRA : 4.90 (-1.80%)
Atara Biotherapeutics, Inc. (ATRA) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

BENSALEM, Pa. , April 3, 2026 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action...

ATRA : 4.90 (-1.80%)
ATRA INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Atara Biotherapeutics (ATRA) Investors of Securities Class Action Deadline on May 22, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Atara To Contact Him Directly To Discuss Their Options

ATRA : 4.90 (-1.80%)
Deadline Alert: Atara Biotherapeutics, Inc. (ATRA) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit

Glancy Prongay Wolke & Rotter LLP reminds investors of the upcoming May 22, 2026  deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased...

ATRA : 4.90 (-1.80%)
Pomerantz Law Firm Announces the Filing of a Class Action Against Atara Biotherapeutics, Inc. and Certain Officers - ATRA

NEW YORK , April 2, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Atara Biotherapeutics, Inc. ("Atara" or the "Company") (NASDAQ: ATRA) and certain...

ATRA : 4.90 (-1.80%)
Deadline Approaching: Atara Biotherapeutics, Inc. (ATRA) Shareholders Who Lost Money Urged To Contact Law Offices of Howard G. Smith

Law Offices of Howard G. Smith reminds investors of the upcoming May 22, 2026 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Atara Biotherapeutics,...

ATRA : 4.90 (-1.80%)
Atara Biotherapeutics, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before May 22, 2026 to Discuss Your Rights - ATRA

NEW YORK , April 1, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Atara Biotherapeutics, Inc. ("Atara Biotherapeutics, Inc." or the "Company") (NASDAQ: ATRA) of a class action...

ATRA : 4.90 (-1.80%)
Law Offices of Frank R. Cruz Encourages Atara Biotherapeutics, Inc. (ATRA) Shareholders To Inquire About Securities Fraud Class Action

The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of shareholders who purchased or otherwise acquired Atara Biotherapeutics, Inc. (“Atara” or the...

ATRA : 4.90 (-1.80%)
ATRA Shareholder Alert: May 22, 2026 Lead Plaintiff Deadline in Atara Biotherapeutics, Inc. Securities Class Action Lawsuit -- The Gross Law Firm

NEW YORK , March 31, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Atara Biotherapeutics, Inc. (NASDAQ: ATRA).

ATRA : 4.90 (-1.80%)
Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm Encourages Atara Biotherapeutics, Inc. (ATRA) Shareholders To Inquire About Securities Fraud Class Action

Glancy Prongay Wolke & Rotter LLP , a leading national shareholder rights law firm, announces that a securities fraud class action lawsuit has been filed on behalf of investors who purchased or...

ATRA : 4.90 (-1.80%)

Business Summary

Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing therapeutics for serious unmet medical needs, with an initial focus on muscle wasting conditions and oncology. The company's lead programs are focused on myostatin and activin, members of the TGF-beta...

See More

Key Turning Points

3rd Resistance Point 5.60
2nd Resistance Point 5.43
1st Resistance Point 5.21
Last Price 4.90
1st Support Level 4.82
2nd Support Level 4.65
3rd Support Level 4.43

See More

52-Week High 19.15
Fibonacci 61.8% 13.33
Fibonacci 50% 11.53
Fibonacci 38.2% 9.74
Last Price 4.90
52-Week Low 3.92

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.